Supplementary Figure from PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT

Wenchao Zhang,Wei Li,Chi Yin,Chengyao Feng,Binfeng Liu,Haodong Xu,Xin Jin,Chao Tu,Zhihong Li

DOI: https://doi.org/10.1158/0008-5472.26934683.v1

2024-01-01

Abstract:Supplementary Figures of the manuscript

What problem does this paper attempt to address?

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Jiahui Mou,Meijun Huang,Feifei Wang,Xiaoding Xu,Hanqi Xie,Henglei Lu,Mingyang Li,Yu Li,Weiwen Kong,Jing Chen,Ying Xiao,Yiding Chen,Chaochen Wang,Jin Ren

DOI: https://doi.org/10.1158/1541-7786.22527890

2023-01-01

Abstract:Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis
PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT

Wenchao Zhang,Wei Li,Chi Yin,Chengyao Feng,Binfeng Liu,Haodong Xu,Xin Jin,Chao Tu,Zhihong Li

DOI: https://doi.org/10.1158/0008-5472.can-24-0163

IF: 11.2

2024-06-21

Cancer Research

Abstract:Chemoresistance is one of the major causes of poor prognosis in osteosarcoma. Alternative therapeutic strategies for osteosarcoma are limited, indicating that increasing sensitivity to currently used chemotherapies could be an effective approach to improve patient outcomes. Using a kinome-wide CRISPR screen, we identified PRKDC as a critical determinant of doxorubicin (DOX) sensitivity in osteosarcoma. Analysis of clinical samples demonstrated that PRKDC was hyperactivated in osteosarcoma, and functional experiments showed that loss of PRKDC significantly increased sensitivity of osteosarcoma to DOX. Mechanistically, PRKDC recruited and bound GDE2 to enhance the stability of GNAS. The elevated GNAS protein levels subsequently activated AKT phosphorylation and conferred resistance to DOX. The PRKDC inhibitor AZD7648 and DOX synergized and strongly suppressed the growth of osteosarcoma in mouse xenograft models and human organoids. In conclusion, the PRKDC-GDE2-GNAS-AKT regulatory axis suppresses DOX sensitivity and comprises targetable candidates for improving the efficacy of chemotherapy in osteosarcoma.

oncology
Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419837.v1

2023-01-01

Abstract:Supplementary figure S5. DAC treatment did not increase the risk of osteosarcoma proliferation.
Supplementary Figures 1-4 from Glioblastoma Proto-oncogene <i>sec61γ</i> is Required for Tumor Cell Survival and Response to Endoplasmic Reticulum Stress

Zhe‐Ming Lu,Lian Zhou,Patrick Killela,Ahmed Rasheed,Chunhui Di,William E. Poe,Roger E. McLendon,Darell D. Bigner,Christopher V. Nicchitta,Hai Yan

DOI: https://doi.org/10.1158/0008-5472.22383560.v1

2023-01-01

Abstract:Supplementary Figures 1-4 from Glioblastoma Proto-oncogene SEC61γ Is Required for Tumor Cell Survival and Response to Endoplasmic Reticulum Stress
Figure S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Xue Meng,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Li,Xiu‐Ping Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419846.v1

2023-01-01

Abstract:Supplementary figure S2. Gating strategies for flow cytometry analyses.
Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

Jun Wei,Fei Wang,Ling-Yuan Kong,Shuo Xu,Tiffany Doucette,Sherise D. Ferguson,Yuhui Yang,Kayla McEnery,Krishan Jethwa,Olsi Gjyshi,Wei Qiao,Nicholas B. Levine,Frederick F. Lang,Ganesh Rao,Gregory N. Fuller,George A. Calin,Amy B. Heimberger

DOI: https://doi.org/10.1158/0008-5472.22394862.v1

2023-01-01

Abstract:Supplementary Figure Legends - PDF file 70K, Supplementary Figure Legends
Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Tongxin Liu,Quanquan Sun,Qi Li,Hua Yang,Yuqin Zhang,Rong Wang,Xiaoshan Lin,Dong Xiao,Yawei Yuan,Longhua Chen,Wei Wang

DOI: https://doi.org/10.1158/1535-7163.22502823

2023-01-01

Abstract:Supplementary Figure legends
Supplemental Figure Legends from Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma

Jenifer B. Gifford,Wei Huang,Ann E. Zeleniak,Antreas Hindoyan,Hong Wu,Timothy R. Donahue,Reginald Hill

DOI: https://doi.org/10.1158/1535-7163.22508517

2023-01-01

Abstract:Figure legends for the supplemental table and each of the supplemental figures.
Supplementary Figure 1 from Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

Robert J. Cardnell,Ying Feng,Lixia Diao,You-Hong Fan,Fatemah Masrorpour,Jing Wang,Yuqiao Shen,Gordon B. Mills,John D. Minna,John V. Heymach,Lauren A. Byers

DOI: https://doi.org/10.1158/1078-0432.22450607.v1

2023-01-01

Abstract:PDF file - 233K, Plots correlating protein expression for components of the DNA Repair Score not shown in Figure 3.
Supplementary Figures S1-S4 from Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

Ivan S. Donev,Wei Wang,Tadaaki Yamada,Qi Li,Shinji Takeuchi,Kunio Matsumoto,Takao Yamori,Yasuhiko Nishioka,Saburo Sone,Seiji Yano

DOI: https://doi.org/10.1158/1078-0432.22442205

2023-01-01

Abstract:Supplementary Figures S1-S4.
Supplementary Figures and Legends from Targeting PRPK Function Blocks Colon Cancer Metastasis

Tatyana Zykova,Feng Zhu,Lei Wang,Haitao Li,Do Young Lim,Ke Yao,Eunmiri Roh,Sang-Pil Yoon,Hong-Gyum Kim,Ki Beom Bae,Weihong Wen,Seung Ho Shin,Janos Nadas,Yan Li,Weiya Ma,Ann M. Bode,Zigang Dong

DOI: https://doi.org/10.1158/1535-7163.22504792.v1

2023-01-01

Abstract:This file contains 7 Supplementary Figures and associated legends: Supplementary Figure 1. Characterization of the antibody to detect phosphorylated Ser250of PRPK (related to Figure 1B, upper). Supplementary Figure 2. PRPK induces metastasis of colon cancer cells to the liver. Supplementary Figure 3. PRPK induces lung metastasis of human HCT116 or mouse CT26 colon cancer cells. Supplementary Figure 4. EGF induces phosphorylation of PRPK and surviving ex vivo and the combination of 5-FU and FA show synergistic effects against colon cancer growth. Supplementary Figure 5. Pre-treatment with FA combined with 5-FU suppresses colon lung metastasis in mice. Supplementary Figure 6. FA combined with 5-FU suppresses colon lung metastasis in mice Supplementary Figure 7. PRPK regulated colon cancer metastasis independently of p53 status.
Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461800.v1

2023-01-01

Abstract:Figure legends for Supplementary Figure S1 and Figure S2
Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Tao Zuo,Ta-Ming Liu,Xun Lan,Yu-I Weng,Rulong Shen,Fei Gu,Yi-Wen Huang,Sandya Liyanarachchi,Daniel E. Deatherage,Pei-Yin Hsu,Cenny Taslim,Bhuvaneswari Ramaswamy,Charles L. Shapiro,Huey-Jen L. Lin,Alfred S. L. Cheng,Victor X. Jin,Tim H.-M. Huang

DOI: https://doi.org/10.1158/0008-5472.22389515.v1

2023-01-01

Abstract:Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer
Supplementary Figure 2 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Xiaosong Chen,Meizhong Zhao,Mingang Hao,Xueqing Sun,Jinglong Wang,Yan Mao,Lidong Zu,Junjun Liu,Yandong Shen,Jianhua Wang,Kunwei Shen

DOI: https://doi.org/10.1158/1541-7786.22510113.v1

2023-01-01

Abstract:PDF file - 471K, Growth-inhibitory effects of tamoxifen, everolimus, and various PI3K inhibitors on breast cancer cell lines.
Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Amanda Herzog,Yansong Bian,Robert Vander Broek,Bradford Hall,Jamie Coupar,Hui Cheng,Anastasia L. Sowers,John D. Cook,James B. Mitchell,Zhong Chen,Ashok B. Kulkarni,Carter Van Waes

DOI: https://doi.org/10.1158/1078-0432.22445265

2023-01-01

Abstract:PDF file - 1957K, Treatment in UM-SCC xenograft and Tgfbr1/Pten KO mice.
Supplementary Figure from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Chun-Miao Deng,Guo-Geng Zhang,Qin-Wen Liu,Jiao-Jiao Xu,Zhi-Chao Liu,Jing Yang,Tao-Yang Xu,Zhi-Gang Li,Fan Zhang,Bin Li

DOI: https://doi.org/10.1158/0008-5472.23283270

2023-01-01

Abstract:Supplementary figures shows Supplementary figures and figure legends
Supplementary Figure Legends from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Yajing Liu,Monika L. Burness,Rachel Martin-Trevino,Joey Guy,Shoumei Bai,Ramdane Harouaka,Michael Brooks,Shang Li,Alex Fox,Tahra Luther,April Davis,Trenton L. Baker,Justin A. Colacino,Shawn G. Clouthier,Zhi‐Ming Shao,Max S. Wicha,Suling Liu

DOI: https://doi.org/10.1158/1078-0432.22460774.v1

2023-01-01

Abstract:Supplementary figures 1-8 legends
Supplementary Fig. 4 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment

Leonard C. Rogers,Jeff C. Kremer,Caitlyn B. Brashears,Zongtao Lin,Zhixian Hu,Alliny C.S. Bastos,Adriana Baker,Nicole Fettig,Dong Zhou,Kooresh I. Shoghi,Carina A. Dehner,John S.A. Chrisinger,John S. Bomalaski,Benjamin A. Garcia,Toshinao Oyama,Eileen P. White,Brian A. Van Tine

DOI: https://doi.org/10.1158/1078-0432.23952336

2023-01-01

Abstract:Supplemental Figure 4. Validation of gene knockouts and ASS1 expression in MEFs.
Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

K. Mark Parnell,Jason M. Foulks,Rebecca N. Nix,Adrianne Clifford,Jeremy Bullough,Bin Luo,Anna V. Senina,David Vollmer,Jihua Liu,Virgil McCarthy,Yong Xu,Michael Saunders,Xiaohui Liu,Scott Pearce,Kevin B. Wright,Marc O’Reilly,Michael V. McCullar,Koc-Kan Ho,Steven B. Kanner

DOI: https://doi.org/10.1158/1535-7163.22499760.v1

2023-01-01

Abstract:Supplementary Figure Legends - PDF file 41K, Legends for supplemental figures 1-4
Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

Andrew J. Garton,Andrew P.A. Crew,Maryland Franklin,Andrew R. Cooke,Graham M. Wynne,Linda Castaldo,Jennifer Kahler,Shannon L. Winski,April Franks,Eric N. Brown,Mark A. Bittner,John F. Keily,Paul Briner,Chris Hidden,Mary C. Srebernak,Carrie Pirrit,Matthew O'Connor,Anna Chan,Bojana Vulevic,Dwight Henninger,Karen Hart,Regina Sennello,An-Hu Li,Tao Zhang,Frank Richardson,David L. Emerson,Arlindo L. Castelhano,Lee D. Arnold,Neil W. Gibson

DOI: https://doi.org/10.1158/0008-5472.22366923

2023-01-01

Abstract:Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

Supplementary Figure from PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT

Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figures 1-4 from Glioblastoma Proto-oncogene &lt;i&gt;sec61γ&lt;/i&gt; is Required for Tumor Cell Survival and Response to Endoplasmic Reticulum Stress

Figure S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Supplemental Figure Legends from Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma

Supplementary Figure 1 from Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

Supplementary Figures S1-S4 from Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

Supplementary Figures and Legends from Targeting PRPK Function Blocks Colon Cancer Metastasis

Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Supplementary Figure 2 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figure from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Supplementary Figure Legends from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Supplementary Fig. 4 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment

Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

Supplementary Figures 1-4 from Glioblastoma Proto-oncogene <i>sec61γ</i> is Required for Tumor Cell Survival and Response to Endoplasmic Reticulum Stress